drugset / Trial / NCT02893332

Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)

NCT02893332

Phase 3 Terminated 200 enrolled Sichuan Provincial People's Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

To tested if the adding of consolidative SBRT to TKI in EGFR mutated patients with less than or equal to 5 metastatic sites (primary + 5) will improve progression free survival (PFS) compared to TKI alone.

Timeline

Start
2016-01-15
Primary completion
2020-08-30
Completion
2020-08-30

Drugs

EvaluationDrugModalityDoseRoute
Background Erlotinib Small molecule 150 mg Oral
Background Gefitinib Small molecule 250 mg Oral